EGFR and adenocarcinoma: Sun et al. reported smoking, non-adenocarcinoma histology, poor performance status (PS) (Eastern Cooperative Oncology Group ≥2), and lack of prior epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy as factors associated with SREs.